Copley Scientific Introduces Improved Test Set-up for More Representative Inhaled Product Testing
The desire to gain a better understanding of how inhaled products perform in patients has highlighted the importance and value of achieving better correlations between in vitro test data and in vivo performance — better IVIVCs. This deepened interest has been echoed by FDA; for example, through research grants supporting the identification of realistic in vitro clinically relevant representations of the human throat, as well as a dissolution method for inhaled product testing.
To help meet this pressing need for better IVIVCs, Copley Scientific has refined the design of a number of pieces of in vitro testing equipment to enable a streamlined, easy-to-use, and compact test set-up for more clinically representative testing of orally inhaled products (OIPs). The proposed set-up uses new components alongside established equipment to deliver data that represent in vivo behaviour more accurately than data from standard test methodologies, originally designed for application in a QC environment.
Achieving closer correlation between routine laboratory data and the efficiency of drug delivery to specific regions of the lung is an important goal in inhaled product testing. Better IVIVCs support the advancement of new OIP products and technology. They also underpin the secure demonstration of bioequivalence, a critical step in the development of generic OIPs and help reduce the risk of unexpected outcomes in clinical trials.
The proposed new test set-up from Copley Scientific includes the Alberta Idealized Throat (AIT) and the BRS 3000 Breathing Simulator. Adult and child versions of the AIT have a standardised geometry that has been shown to more representatively reflect deposition in the throat than the standard USP induction port used in routine OIP testing. A breathing simulator similarly supports the application of test conditions that are closely matched to the physiology and capabilities of a target patient group.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance